BRIEF: Legend Biotech considers second listing outside U.S.
Cancer treatment maker Legend Biotech Corp. (LEGN.US) is weighing a second listing to complement its existing one in the U.S., with possible venues including Hong Kong, Singapore and London, Bloomberg…
BRIEF: Legend Biotech’s revenue rises 36% in second quarter
Drug maker Legend Biotech Corp. (LEGN.US) on Monday reported strong revenue growth in the second quarter of 2025 as its core cancer drug gained traction. But its net loss also…
NEWS BRIEF: Legend Biotech’s revenue doubles on big gains for CAR-T treatment
Cancer treatment maker Legend Biotech Corp. (LEGN.US) reported on Friday its revenue more than doubled to $187 million in the second quarter from $73 million a year earlier, while its…
Will Genscript cash out of Legend Biotech in the face of fat profit temptation?
A potential sale of Legend Biotech may carry a 30% to 50% premium, which could generate up to 55.8 billion yuan for Genscript based on its 48% stake in the…
GenScript losses shrink on strong growth for cancer cell therapy
The pharma company’s losses narrowed 58% last year, as its life sciences and cell therapy businesses experienced strong growth Key Takeaways: GenScript’s cell therapy revenue grew by 143.7% last year…
FAST NEWS: Genscript’s controlling shareholder sells shares to Hillhouse Capital
The latest: Genscript Biotech Corp. (1548.HK) announced Wednesday its controlling shareholder Genscript Corp. will sell 85.78 million shares, or about 0.4% of its shares, to GNS II Holdings Ltd, a subsidiary…
FAST NEWS: Genscript’s new cancer drug sales surge in third quarter
The latest: Legend Biotech Corp. (LEGN.US), a cell therapy subsidiary of Genscript Biotech Corp. (1548.HK), announced Tuesday that sales of its Carvykti cancer drug jumped 176% to $152 million in the third quarter…
